Your brand tagline.
Infants
Fitness
Clinical Trials
Suite 506, Level 5
50 Clarence St
Sydney, NSW 2000, Australia
P: +61 2 9078 8180
E: info@bioxyne.com
ABN: 97 084 464 193
Select a page for this section using the sidebar.
Atopic dermatitis (AD), also known as eczema, is a common inflammatory skin disease affecting 10% of the population.
Eczema has a negative impact on quality of life; visual issues aside, it can be uncomfortably itchy and sore.
The first signs of atopic dermatitis usually appear early in life, from about six months of age, and often precede other allergic diseases such as asthma or allergic rhinitis. The majority of cases (at least 60%) arise within the first year of life.
The symptoms in young children are characterised by dry and scaly patches on the scalp, forehead, and face. These patches are very common on the cheeks.
A clinical study has shown that the probiotic Lactobacillus fermentumVRI-003 (otherwise known as Bioxyne’s PCC®) may alleviate the symptoms of eczema in infants.
Notably, the improvement in symptom severity with PCC® treatment was still evident two months after the treatment stopped.In a follow up scientific study, this was shown to be associated with the ability of PCC® to activate and boost the body’s immune response.
Bioxyne’s Chief Scientific Officer Dr Peter French reviews the findings of these studies in the White Paper: Probiotics in the treatment of atopic dermatitis
Read more about each of the two studies:
Effects of probiotics on atopic dermatitis
Clinical effects of probiotics are associated with increased interferon-g responses in very young children with atopic dermatitis.
